Teva Pharmaceuticals
TEVA
435 hedge funds and large institutions have $5.66B invested in Teva Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 130 increasing their positions, 133 reducing their positions, and 42 closing their positions.
60% more call options, than puts
Call options by funds: $277M | Put options by funds: $174M
51% more capital invested
Capital invested by funds: $3.74B → $5.66B (+$1.92B)
46% more funds holding in top 10
Funds holding in top 10: 13 → 19 (+6)
29% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 42
5.25% more ownership
Funds ownership: 44.22% → 49.48% (+5.3%)
2% more funds holding
Funds holding: 428 → 435 (+7)
2% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 133
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$258M |
| 2 |
SPC
Slate Path Capital
New York
|
+$106M |
| 3 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$89.7M |
| 4 |
SSM
Sound Shore Management
Greenwich,
Connecticut
|
+$73.8M |
| 5 |
IAM
Ion Asset Management
Herzliya,
Israel
|
+$53.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$94M |
| 2 |
Millennium Management
New York
|
-$38.8M |
| 3 |
Jane Street
New York
|
-$36.8M |
| 4 |
Renaissance Technologies
New York
|
-$23.5M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$23.5M |
TEVA Hedge Fund Activity: Q3 2023 in Review
435 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2023, worth a combined $5.66B — up 51% from $3.74B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new TEVA positions and 42 closed out — a net gain of 12 holders — while 130 added to existing stakes and 133 trimmed.
The largest buyer was Harel Insurance Investments & Financial Services, adding an estimated $258M. The largest seller was Norges Bank, cutting an estimated $94M.
- 435 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2023, up from 428 in Q2 2023.
- Funds reported $5.66B of Teva Pharmaceuticals stock for Q3 2023, up 51% quarter-over-quarter.
- 54 funds opened new Teva Pharmaceuticals positions in Q3 2023 and 42 closed out, a net change of +12 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2023 was Harel Insurance Investments & Financial Services, an estimated $258M added.
- The largest Teva Pharmaceuticals seller in Q3 2023 was Norges Bank, an estimated $94M sold.
Based on aggregated 13F filings for Q3 2023.